Our observation that KRAS/BRAF wild-type and mutated tumors had overlapping kinase activity profiles is consistent with the increasing recognition of tumor heterogeneity, reflected in disparate mutation status, as determinant of variable response to anti-EGFR antibody therapy. This evidence concerns the gene EGFR and neoplasm.